- Trials with a EudraCT protocol (409)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (189)
409 result(s) found for: Observational study.
Displaying page 6 of 21.
EudraCT Number: 2014-002317-32 | Sponsor Protocol Number: SOFOLT-2 | Start Date*: 2014-10-29 |
Sponsor Name:Azienda Ospedaliera Papa Giovanni XXIII [...] | ||
Full Title: An Open-Label Study to Explore the Clinical Efficacy of GS 7977 (Sofosbuvir -Sovaldi®) with Ribavirin as Pre-Emptive Administration in Transplant-Recipients with Hepatitis C Virus (HCV) active infe... | ||
Medical condition: HCV active infection at the time of OLT | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004674-42 | Sponsor Protocol Number: GS-US-334-1113 | Start Date*: 2015-11-20 | ||||||||||||||||
Sponsor Name:Gilead Sciences, Inc. | ||||||||||||||||||
Full Title: A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials | ||||||||||||||||||
Medical condition: Chronic Hepatitis C virus infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003401-26 | Sponsor Protocol Number: 400-12-006 | Start Date*: 2014-05-16 |
Sponsor Name:Ethicon Inc. | ||
Full Title: A Prospective, Randomized, Controlled, Study Evaluating EVICEL® Fibrin Sealant as an Adjunct to Hemostasis During Abdominal, Retroperitoneal, Pelvic or Thoracic (Non‐Cardiac) Surgery in Pediatric P... | ||
Medical condition: Abdominal, Retroperitoneal, Pelvic or Thoracic (Non‐Cardiac) Surgery | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002957-46 | Sponsor Protocol Number: 56021927PCR3015 | Start Date*: 2020-05-13 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with Hormone-Sensitive Pr... | |||||||||||||
Medical condition: High risk recurrent prostate cancer previously treated with radical prostatectomy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000452-34 | Sponsor Protocol Number: 3004 | Start Date*: 2013-11-19 | |||||||||||
Sponsor Name:Steno Diabetes Center | |||||||||||||
Full Title: Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria | |||||||||||||
Medical condition: Patients with type 2 diabetes mellitus and normoalbuminuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) IT (Completed) GB (Completed) NL (Completed) ES (Completed) CZ (Completed) GR (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002201-25 | Sponsor Protocol Number: CHDR2007 | Start Date*: 2020-12-14 |
Sponsor Name:Centre for Human Drug Research | ||
Full Title: A two-part (observational and intervention) study to explore disease characteristics of vulvar (pre)malignancies compared to healthy volunteers | ||
Medical condition: lichen sclerosus, vulvar (pre)malignancies | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001957-17 | Sponsor Protocol Number: DFNS02 | Start Date*: 2015-10-21 | |||||||||||
Sponsor Name:Umeå University Hospital | |||||||||||||
Full Title: THE EFFECT OF DIFLUNISAL ON FAMILIAL TRANSTHYRETIN AMYLOIDOSIS: An open label phase III extension study of the diflunisal trials (IND 68092 and DFNS01), and an open label observational study on p... | |||||||||||||
Medical condition: Familial transthyretin amyloidosis complicated by cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001505-22 | Sponsor Protocol Number: BST-COVID-01 | Start Date*: 2020-04-23 | |||||||||||
Sponsor Name:Banc de Sang i Teixits | |||||||||||||
Full Title: Double-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000157-41 | Sponsor Protocol Number: UoL001343 | Start Date*: 2019-06-07 | |||||||||||
Sponsor Name:The University of Liverpool | |||||||||||||
Full Title: NEO21-RS: A phase II randomised study of the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with oestrogen suppression therapy versus oestrogen suppression therapy alone as neoadj... | |||||||||||||
Medical condition: ER-positive, HER2-negative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005722-35 | Sponsor Protocol Number: H--6-2014-070 | Start Date*: 2015-06-23 | ||||||||||||||||
Sponsor Name:Glostrup University Hospital | ||||||||||||||||||
Full Title: Measures of inflammation in low back pain (LBP) and anti-TNFα for the treatment of deemed discogenic LBP - an explorative study | ||||||||||||||||||
Medical condition: Low back pain with and without legg-pain In the late periode 1990ies it became clear that various cytokines and other inflammatory elements played a large role for low back pain. One of the known ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004110-20 | Sponsor Protocol Number: 78666 | Start Date*: 2022-10-12 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Improving symptomatic treatment with pyridostigmine and amifampridine: a randomized double-blinded, placebo controlled crossover trial in patients with myasthenia gravis (IMPACT-MG) | |||||||||||||
Medical condition: Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002539-13 | Sponsor Protocol Number: CARE-ROP | Start Date*: 2014-04-01 | |||||||||||
Sponsor Name:University Medical Center Freiburg | |||||||||||||
Full Title: Multicenter randomized double masked parallel design exploratory study to assess safety and efficacy of two different doses of intravitreal anti-VEGF treatment with ranibizumab (0.12 mg vs. 0.20 mg... | |||||||||||||
Medical condition: retinopathy of prematurity | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019102-17 | Sponsor Protocol Number: Y-55-52120-147 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Ipsen Pharma SAS | |||||||||||||
Full Title: A PHASE III, PROSPECTIVE, MULTICENTRE, OPEN LABEL, EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND EFFICACY OF REPEATED TREATMENT WITH DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN C... | |||||||||||||
Medical condition: Lower limb spasticity in children with dynamic equinus foot deformity due to cerebral palsy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003589-42 | Sponsor Protocol Number: SP848-AKEx-1209 | Start Date*: 2013-01-16 | |||||||||||
Sponsor Name:Spirig Pharma AG | |||||||||||||
Full Title: Observational (non-interventional), follow-up trial assessing long-term local tolerability and efficacy (recurrence rate) of resiquimod gel in patients treated for actinic keratosis. | |||||||||||||
Medical condition: Actinic Keratosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000341-13 | Sponsor Protocol Number: OTV.PRE.01 | Start Date*: 2012-08-28 | ||||||||||||||||
Sponsor Name:Weber & Weber GmbH & Co. KG | ||||||||||||||||||
Full Title: Efficacy and Safety of an Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence: A Placebo Controlled, Randomized, Double-blinded Parallel-Grou... | ||||||||||||||||||
Medical condition: recurrent acute otitis media | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023988-17 | Sponsor Protocol Number: 260777 | Start Date*: 2014-04-04 | |||||||||||
Sponsor Name:BrepCo Biopharma Limited | |||||||||||||
Full Title: Management of Hypotension In the Preterm: A multi centre, randomised, controlled trial of hypotension management in the extremely low gestational age newborn | |||||||||||||
Medical condition: Low Blood Pressure | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022284-35 | Sponsor Protocol Number: R00002 CR 301 (ORF) | Start Date*: 2011-03-08 | |||||||||||
Sponsor Name:ORFAGEN | |||||||||||||
Full Title: CLINICAL EFFICACY AND SAFETY OF TAZAROTENE CREAM 0.05% IN THE INITIAL AND MAINTENANCE THERAPIES OF LAMELLAR ICHTHYOSIS (LI) | |||||||||||||
Medical condition: Lamellar Ichthyosis (LI) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SE (Completed) DE (Completed) FR (Ongoing) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021070-11 | Sponsor Protocol Number: 005/05E | Start Date*: 2010-11-23 |
Sponsor Name:BioVex Inc | ||
Full Title: An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment with OncoVEX GM-CSF or GM-CSF for Eligible Melanoma Patients Participating in Study 005/05 | ||
Medical condition: Unresectable Stage IIIb, IIIc and IV Melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018370-21 | Sponsor Protocol Number: C-II-007 | Start Date*: 2010-05-27 | |||||||||||
Sponsor Name:CESAR Central European Society for Anticancer Drug Research EWIV | |||||||||||||
Full Title: Phase I/II study with Temsirolimus versus no add-on in patients with castration resistant prostate cancer (CRPC) receiving first-line Docetaxel chemotherapy CESAR Study in Prostrate Cancer wi... | |||||||||||||
Medical condition: castration resistant prostate cancer (CRPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004753-87 | Sponsor Protocol Number: BBI608-901 | Start Date*: 2020-03-18 |
Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc. | ||
Full Title: A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Sumitomo Dainippon Pharma Oncology, Inc. sponsored Napabucasin Protocols | ||
Medical condition: Metastatic Pancreatic Adenocarcinoma and Metastatic Colorectal Cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
